(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.
Cervomed's earnings in 2026 is -$25,584,991.On average, 9 Wall Street analysts forecast CRVO's earnings for 2026 to be -$17,868,851, with the lowest CRVO earnings forecast at -$26,205,551, and the highest CRVO earnings forecast at -$5,246,292. On average, 6 Wall Street analysts forecast CRVO's earnings for 2027 to be -$13,590,394, with the lowest CRVO earnings forecast at -$18,951,419, and the highest CRVO earnings forecast at -$3,303,221.
In 2028, CRVO is forecast to generate -$11,702,839 in earnings, with the lowest earnings forecast at -$19,223,449 and the highest earnings forecast at -$3,497,528.